BIOTRONIK adds New “Reocor” External Pacemaker to its High-Quality Product Portfolio

Reocor combines intuitive design with unprecedented longevity

BERLIN--(BUSINESS WIRE)-- BIOTRONIK SE & Co. KG today announced the European launch after receiving CE Mark approval for its new Reocor external pacemakers, available in two models for dual and single chamber pacing therapy.

Quality based on 25 years of experience
BIOTRONIK continues to enrich its high quality product portfolio with the launch of the new external pacemakers. Reocor offers complete reliability in emergencies and temporary patient care, setting a new quality standard for external pacing therapy.

Reocor – Intuitive design for safe usage in daily practice
The new Reocor has an intuitive design for simplified usage and extended longevity that increases reliability and reduces costs over time. Simplified usage is achieved by the function dials displaying selectable parameter values and visualizing programmed settings at a glance. Thus, easy handling is guaranteed without any specific training requirements. Extended battery service times of up to 25 days for permanent pacing therapy, supplemented with a backup power supply during battery replacement, ensure patient safety and longer continuous usage in daily practice. Reocor has also been enhanced to accommodate high pacing outputs and high pacing rates being especially important for pediatric care. Therefore Reocor effectively delivers individual solutions for a broad range of patients.

“Reocor represents the first in a series of advanced new external devices that BIOTRONIK will launch. In 2010 we will be offering a new external pacemaker, a new pacing system analyzer and a completely new programmer which demonstrates our commitment to develop the highest quality and the most complete CRM product portfolio. Reocor represents the ultimate promise of reliability to our customers with clear advantages in its ease of use, unsurpassed longevity, and convenient mobility in a small and lightweight housing,” stated Marlou Janssen, Vice President, Global Marketing and Sales, Cardiac Rhythm Management, BIOTRONIK.

As one of the world’s leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of more than 5,100 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.

More information:

Upon publication, please provide us with a copy.


Sandy Hathaway, Senior Director, Corporate Communications
Tel. + 49 (0) 30 68905 1602
Email: [email protected]

KEYWORDS:   Europe  Asia Pacific  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Hospitals  Medical Devices



Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.